Infektološki glasnik, Vol. 38 No. 2, 2018.
Izvorni znanstveni članak
Active Ocular Toxoplasmosis in Patients Diagnosed and Treated at General Hospital Zadar
Ana Pupić-Bakrač
orcid.org/0000-0002-8493-7305
; Department of Ophthalmology, General Hospital Zadar
Samir Čanović
; Department of Ophthalmology, General Hospital Zadar
Ana Didović Pavičić
; Department of Ophthalmology, General Hospital Zadar
Marija Škara Kolega
; Department of Ophthalmology, General Hospital Zadar
Jure Pupić-Bakrač
; Department of Otorhinolaryngology and Maxillofacial surgery, General Hospital Zadar
Sažetak
Toxoplasma gondii is responsible for the 20-60% of all the cases of chorioretinitis. Causes of permanently reduced vision (found in about 25% of the patients) include macular active lesions and macular oedema, optic nerve involvement, vascular occlusion, retinal detachment, and late secondary choroidal neovascularization.
A retrospective, non-consecutive chart review was performed on 11 patients with active ocular toxoplasmosis. At examination, all patients had central active lesions on retina. Preexisting chorioretinal scars were found in seven patients (63.6%). Eight patients (72.7%) had vitritis, while three patients (27,3%) had iridocyclitis. Six patients (54.6 %) had macular inflammatory lesions, four (36,37%) of them had active lesions out of vascular arcades, and one (9.1%) had active lesions inside vascular arcades, while macula was not affected. The mean value of visual acuity at first visit of the patients was 0,5. The mean value of visual acuity was 0.9 after the healing process. All the patients were treated with oral antibiotics. Seven patients also received oral corticosteriods, and seven of them were also treated with pyrimethamine. All patients with signs of iridocyclitis were also treated with topical corticosteroids. Although toxoplasmosis chorioretinitis is usually a self-limited infection and generally resolves spontaneously, unrecognised cases can result in severe visual impairments.
Ključne riječi
toxoplasmosis; ocular; chorioretinitis; therapeutics
Hrčak ID:
226057
URI
Datum izdavanja:
10.10.2019.
Posjeta: 1.850 *